| 2026-10-22 16:30 |
8-K |
["5.07"] |
other |
0.25
|
Shareholder vote to increase authorized shares; routine corporate action with weak M&A signal. |
SEC · detail |
| 2026-09-14 09:28 |
8-K |
["1.01", "7.01", "9.01"] |
material agreement |
0.12
|
Settlement and license amendment with Nerviano; unrelated to M&A activity. |
SEC · detail |
| 2026-08-11 16:11 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine earnings announcement; no M&A signals present. |
SEC · detail |
| 2026-07-16 08:38 |
8-K |
["1.01", "8.01", "9.01"] |
other |
0.05
|
Cardiff Oncology completed a $10.05M equity financing with institutional investors and insiders; no M&A signal. |
SEC · detail |
| 2026-06-11 16:15 |
8-K |
["5.07"] |
other |
0.05
|
Routine annual shareholder meeting voting results; no M&A indicators present. |
SEC · detail |
| 2026-06-03 08:30 |
8-K |
["7.01", "9.01"] |
other |
0.05
|
Routine investor presentation on Phase 2 clinical data; no M&A signals detected. |
SEC · detail |
| 2026-05-29 17:11 |
8-K |
["1.01"] |
other |
0.05
|
Contractual dispute and license termination notice; no M&A signal. |
SEC · detail |
| 2026-05-19 17:01 |
8-K |
["8.01"] |
other |
0.05
|
Litigation filing against NMS regarding license agreement dispute; no M&A signal. |
SEC · detail |
| 2026-05-14 16:15 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine Q1 2026 earnings announcement with no M&A-related language or indicators. |
SEC · detail |